AdipoGen Life Sciences


CHF 120.00
In stock
AG-CP3-0043-M0055 mgCHF 120.00
AG-CP3-0043-M02525 mgCHF 360.00
AG-CP3-0043-M100100 mgCHF 1'100.00

BULK available!

Learn more about GLP-1 & GIP Receptor Agonists

More Information
Product Details
Synonyms LY3298176
Product Type Chemical


MW 4813.5


CAS 2023788-19-2
Source/Host Chemicals Synthetic.
Purity Chemicals ≥98% (HPLC)
Appearance White lyophilized powder.
Solubility Soluble in aqueous solution (5% AcOH) (1mg/ml).
Smiles N[C@H](C(NC(C)(C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@H](O)C)([H])C(N[C@H](C(N[C@]([C@H](O)C)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@]([C@@H](C)CC)([H])C(NC(C)(C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CCCCN)C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(NCC(NCC(N1CCC[C@H]1C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@H](C(N2CCC[C@H]2C(N3CCC[C@H]3C(N4CCC[C@H]4C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O)=O)=O)CC7=CC=CC=C7)=O)C)=O)=O)=O)C)=O)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)CC(C=C8)=CC=C8O)=O)CC(O)=O)=O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)=O)=O)CC%10=CC=C(O)C=C%10
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.
  • Tirzepatide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.

  • Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains two non-coded amino acid residues (Aib, α-amino isobutyric acid) at positions 2 and 13).

Product References
  1. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept: T. Coskun, et al.; Mol. Metab. 18, 3 (2018)
  2. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial: J.P. Frias, et al.; Lancet 392, 2180 (2018)
  3. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors: E. Yuliantie, et al.; Biochem. Pharmacol. 177, 114001 (2020)
  4. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists: S. Urva, et al.; Diabetes Obes. Metab. 22, 1886 (2020)
  5. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes: J.P. Frias; Expert Rev. Endocrinol. Metab. 15, 379 (2020) (Review)
  6. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes: M.K. Thomas, et al.; J. Clin. Endocrinol. Metab. 106, 388 (2021)
  7. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review: V.P. Chavda, et al.; Molecules 27, 4315 (2022) (Review)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.